echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Renfu Medicine's Class 1.1 new drug Bairesi Pills was approved for clinical trials

    Renfu Medicine's Class 1.1 new drug Bairesi Pills was approved for clinical trials

    • Last Update: 2022-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Bairesi Pills jointly developed by Wuhan Renfu Innovative Drug Research and Development Center Co.
    , Ltd.
    , a wholly-owned subsidiary of Renfu Pharmaceutical Group, and the Uyghur Medical Research Institute of Xinjiang Uygur Autonomous Region received the approval notice for drug clinical trials issued by the State Food and Drug Administration

    .

    Bairesi Pill is derived from the nosocomial preparations included in the "Preparation Standards for Uyghur Medical and Medical Institutions in Xinjiang Uygur Autonomous Region".
    It is applied for clinical trials in accordance with the requirements of Class 1.
    1 innovative traditional Chinese medicines in the registration classification of traditional Chinese medicines, and is intended to be used for the treatment of stable vitiligo

    .
    At present, calcineurin inhibitors, vitamin D3 derivatives and hormone drugs are mainly used in the clinical treatment of vitiligo

    .

    As a cooperative research and development project, the ownership and disposal rights of Bairesi Pills related technologies and their intellectual property rights belong to Wuhan Renfu Innovative Drug Research and Development Center
    .
    According to the requirements of laws and regulations related to drug registration in China, Wuhan Renfu Innovative Drug Research and Development Center and Xinjiang Uygur Autonomous Region Uyghur Medical Research Institute will start the work related to clinical research of drugs after receiving the notice of drug clinical trial

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.